Effect of mergers and acquisitions on drug discovery: perspective from a case study of a Japanese pharmaceutical company

Sotaro Shibayama,Kunihiro Tanikawa,Ryuhei Fujimoto,Hiromichi Kimura
DOI: https://doi.org/10.1016/j.drudis.2007.10.015
Abstract:The pharmaceutical industry has experienced intermittent waves of mergers and acquisitions (M&As) since the 1980s and recently appeared to be in yet another wave. Previous studies indicated rather negative impacts of consolidation on research and development, suggesting that they do not necessarily lead to long-term reinforcement of research capabilities, although they may enrich the drug pipeline in the short term. However, recent studies have implied a positive side in terms of knowledge-base transfer. Further micro-organizational studies suggested that scientists learned new knowledge and approaches from partner scientists and improved their performance and innovation. These findings imply that measures for the scientist-level integration after M&As would reinforce fundamental research capabilities in the long term.
What problem does this paper attempt to address?